Audited Financial Results for the quarter and year ended 31st March, 2026
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma reported audited consolidated results for FY2026. Revenue from operations declined to ₹40,783 million from ₹44,295 million in FY2025, an 8% decrease. Profit after tax attributable to owners fell to ₹14,185 million from ₹18,854 million, a 25% decline. Standalone revenue was ₹35,946 million (down from ₹40,945 million) with net profit of ₹12,815 million (down from ₹18,504 million). The auditors issued unmodified opinions on both standalone and consolidated financial statements. The company completed acquisition of 35.75% stake in Adcock Ingram Holdings Limited (South Africa) in November 2025 for ₹19,912 million plus ₹879 million in transaction costs. A deferred tax asset of ₹1,150 million was recognized due to remeasurement under the new 22% tax rate option. Total dividend for FY2026 is ₹5 per share of ₹2 face value.
The stock may face pressure due to significant revenue and profit decline of approximately 8% and 25% respectively year-on-year. However, positive operating cash flow of ₹17,683 million and the new acquisition may provide some support. The agrochemical business demerger into a separate entity is in progress.